Birmingham, Mary C.

Prevention of bleeding in patients with atrial fibrillation undergoing PCI

Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular Diseases

Cited by 1,590

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy

Antibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance

Cited by 1,101

Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program

Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases

Antimicrobial Resistance in StaphylococcusAntibiotics Pharmacokinetics and Efficacy

Cited by 428

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics

Antibiotics Pharmacokinetics and EfficacyNeutropenia and Cancer Infections

Cited by 306

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 245